BIOEMTECH Information

BIOEMTECH’s mission and passion is accelerating preclinical research of promising drugs, towards clinical translation, through precisely targeted services and products. BIOEMTECH leverages its own boutique laboratories to drive innovation and ensure quality, for evaluating new compounds in all stages of preclinical testing, GLP toxicology and alpha emitters therapy schemes. It has developed the eyesTM desktop cameras for real-time in vivo imaging of SPECT and PET radionuclides and dyes. The eyesTM offer unmatched excellence in the challenging in vivo imaging of alpha emitters (212Pb & 225Ac) for oncological models, in short scanning times and clinically relevant doses. Both in BIOEMTECH’s services and products, fast screening applications are a core company value towards accelerating drug development. Finally, BIOEMTECH is active as an preclinical partner in several projects including H2020, FET, ERA, ITN and more. The company was funded by the Action of the Competitiveness Programme (NSRF 2021-2027) "Green Productive Investment of SMEs" of the "Green Transition SMEs" Action Cluster. The Action aims at the exploitation and development of modern technologies by SMEs, the upgrading of their products/services and activities in general.